Business Wire

DNBC-FINANCIAL-GROUP

13.4.2022 18:35:14 CEST | Business Wire | Press release

Share
5 Reasons to Make International Business Payments via Business Account - DNBC Financial Group

To make a big achievement in today's global economy and win sales against overseas competition, businesses must provide their clients with appealing sales conditions accompanied by proper international business payments mechanisms. The most common way to pay international business invoices is via bank wire transfer or credit unions, yet the currency exchange rate is high.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220413005543/en/

Another option is believed to be one of the best international payment solutions for business is via online payment providers. DNBC now will show you 5 reasons to make international business payments via business account to avoid losing potential customers to competition by failing to consider other payment choices.

1. Being Transparent

Businessmen are concerned they would be charged high fees if they want to make international business payments. Making cross-border payments may be complicated and costly due to hidden fees and confusing exchange rate calculations. Make sure you always know the exchange rates and costs associated with money transfer services prior to making a transaction.

2. Transferring around the world in multiple currencies

Cash is still preferred when making purchases, but not everyone is willing to accept it, especially when making international business payments. Paying mortgages and other invoices in a foreign nation is a tremendous demand for any businessman.

At DNBC Financial Group , we enable SWIFT and SEPA transfers to 170 countries and territories worldwide, providing our clients with a range of transfer alternatives at the lowest possible rate and with the least amount of wait time.

3. Organizing Your Business Records

Having a business checking account to make international business payments is a great idea for businessmen to manage their firm. The account may store both receipts and expenditure checks, which helps you keep track of costs, check up on spending, avoid overspending and calculate profit margin in an easy way.

With DNBCnet Mobile App , you may check the balance on your payment card at any time and from any location through DNBCnet, SMS Banking, or any ATM. Moreover, we also support exporting e-statements of your transactions over the course of a month or many months.

4. Transferring Limits

The maximum amount per transaction is one of the top requirements for creating a business checking account. Some suppliers need a minimum payment, while others have no restrictions at all. Finding a source or provider that can consistently meet your company's demands is critical.

Here at DNBC, the transaction limit can come up to 500 000 EUR/ day for business accounts.

5. Transferring Speed

Since making international business payments via bank transfer requires the person to visit the physical bank and fill out paperwork, it is considered to be extremely time-consuming. Or, when you need an instant transfer, credit unions can be the best bet. However, fees for these services are charged higher than other methods!

Online payment providers like DNBC provide lower transaction costs and the same advantages. It takes one to three business days to process most currencies, but some currencies may take longer. Here is DNBC Financial Group's average transaction speed:

- SWIFT services for international transfer: 02-05 business days
- SEPA for Eurozone transfer: 01-02 business days

Make International Payments Via Business Accounts With DNBC

DNBC Financial Group strives to become the best business account for international payments. We offer full online banking experience, money transactions in over 170 countries with multiple currencies, and are always ready to support you 24/7. Find out how DNBC can help you make international payments better.

Link:

ClickThru

Social Media:

https://www.facebook.com/dnbcfinancialgroup/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye